Twelve Million Lose Coverage for GLP-1 Obesity Drugs
Twelve million patients lost insurance coverage for each of Eli Lilly's Zepbound and Novo Nordisk's Wegovy between 2025-2026, forcing patients to pay out-of-pocket or seek alternative compounded medications.
Objective Facts
A GoodRx analysis found that from 2025 to 2026, 12 million people lost coverage for Zepbound and 12 million lost coverage for Wegovy. CVS Caremark dropped Eli Lilly's Zepbound from coverage starting July 2025, and 88% of people who retain coverage face restrictions like prior authorization or BMI requirements of 40 or higher. At the state level, only 13 states provided Medicaid coverage for weight loss GLP-1s as of January 2026, down from 16 in 2025. Physicians report administrative burdens increasing as they become financial planners; Dr. Catherine Varney noted around 60% of her 1,000 obesity drug patients pay out of pocket, with some finding it cheaper to pay cash than to meet deductibles.
Left-Leaning Perspective
The left-leaning coverage centered on insurance companies' apparent arbitrary decision-making in denying coverage. Tracy Zvenyach of the Obesity Action Coalition, quoted in NPR's April 22 coverage, criticized insurers for "making it up" when setting formulary restrictions and eligibility criteria. GoodRx's Amanda Nguyen emphasized in the same NPR piece that patients without coverage face a choice between affording medication and forgoing treatment—a framing that highlighted access inequity. Penn LDI's research, published January 21, 2026, documented how Pennsylvania eliminated Medicaid coverage entirely, describing the decision as a disruption of care for patients already benefiting from treatment. The progressive framing treats insurance coverage decisions as a justice issue: patients are being denied a proven medical intervention based on cost concerns that primarily serve corporate interests. Left-leaning analysis focuses on what insurers and state governments omit: acknowledgment that obesity is a recognized medical condition deserving coverage comparable to other chronic disease treatments. The criticism centers on prior authorization barriers set at BMI 40 (vs. the clinical definition of 30) and formulary restrictions that force patients to switch between incompatible medications or turn to unregulated alternatives. Amanda Nguyen's comment that patients must "forgo" medication underscores the left's view that coverage denials create health equity problems. What left coverage tends to downplay: the actual cost pressures facing insurers and state budgets, the role of manufacturer pricing in driving coverage decisions, and whether GLP-1s for weight loss represent a fiscally sustainable expansion of insurance benefits. The NPR story includes CVS Caremark's argument about manufacturer pricing, but it is presented as a counterargument to the main narrative of access loss.
Right-Leaning Perspective
The right-leaning and industry perspective, evident in statements from CVS Caremark and the Pharmaceutical Care Management Association, pins responsibility for coverage gaps on manufacturer pricing. Phillip Blando of CVS Caremark stated in NPR's April 22 coverage that "the egregiously high list prices set by drug manufacturers...are the single biggest barrier to patient access"—a formulation that deflects responsibility from insurance formulary decisions to pharmaceutical companies. The PCMA's Greg Lopes asserted that employers and PBMs have made "huge progress" on coverage expansion, suggesting the industry is solving the problem without government intervention. The Axios reporting on April 21 framed the Trump administration's decision to delay the BALANCE program and instead use taxpayer Medicare dollars for coverage as a practical concession to insurers' feasibility concerns, rather than a failure of the private insurance market. Conservative analysis emphasizes that formulary restrictions serve a legitimate cost-control function and that competition among drugs (Zepbound vs. Wegovy) incentivizes price reductions. The American Action Forum's November 13 analysis critiqued the administration's GLP-1 deal as an "administrative end-run around normal coverage determinations," warning that pre-setting a $50 copay federally bypasses the decentralized, clinically-driven formulary process—a market-skeptical argument that regulators and politicians should not override plan sponsor decision-making. This perspective treats insurance restrictions as necessary fiscal discipline, not denial of care. What right-leaning coverage tends to downplay: the scale of coverage loss (12 million per drug) and the human impact of formulary restrictions; the observation that manufacturers have negotiated tariff relief and industrial policy sweeteners alongside price agreements, suggesting the "free market" framing is incomplete.
Deep Dive
The core story reflects a structural tension in U.S. health insurance: GLP-1 obesity drugs are effective and increasingly in demand, but at list prices over $1,000/month, they threaten the financial sustainability of both employer plans and public programs. Between 2025 and 2026, insurance formularies became more restrictive, not more generous, despite the administration's announced price deals and the emergence of government bridge programs. The key actors tell different stories about why. Insurance companies and industry groups blame manufacturer pricing: CVS Caremark's decision to drop Zepbound in favor of Wegovy is presented as competition driving down costs, not denial of care. Advocacy groups and clinicians blame insurance company decision-making: Tracy Zvenyach's critique that insurers are "just making it up" suggests formulary policies lack principled clinical rationale. The evidence supports both framings partly. GLP-1 list prices have been high ($1,000+ monthly), and insurers are making unilateral choices about which drugs to cover. However, the Trump administration's November 2025 manufacturer agreements reduced cash prices to $350/month, and the April 2026 decision to extend the Medicare GLP-1 Bridge instead of implementing BALANCE suggests even discounted public pricing may be fiscally challenging for the private market to absorb. What each perspective misses: The left underestimates the genuine cost pressures facing insurers and states; restricting coverage to the most obese patients (BMI 40) is not purely arbitrary—it is a rationing mechanism to manage demand within limited budgets. The right understates the scale of access loss: 12 million people per drug lost coverage in a single year, and only 13 states cover weight-loss GLP-1s through Medicaid. The right also glosses over the fact that manufacturer price agreements included tariff relief and expedited FDA review, making them partly industrial policy rather than pure market solutions. Neither side adequately addresses whether obesity should be treated as a chronic disease warranting universal coverage (like diabetes) or as a lifestyle choice with limited public responsibility. Looking forward, the critical question is whether state Medicaid programs and Medicare Part D plans will voluntarily adopt the BALANCE model starting in 2027 if it remains voluntary. If participation is low, coverage gaps will persist, forcing patients to compounded drugs or out-of-pocket payment. The April 21 announcement that BALANCE would not be mandatory in Medicare suggests the administration expects low take-up from private plans, explaining why it extended the taxpayer-funded Bridge. This outcome—government backstopping private insurance's inability to absorb GLP-1 costs—may itself become a political flashpoint between those viewing it as proper public investment in health and those viewing it as market failure requiring deeper insurance reform.